Biomarin Pharmaceutical Aktie News

BioMarin has both a solid revenue portfolio of several products and a promising pipeline. The market's main concern has been TransCon competition; however, the combination of Voxzogo and BMN 333 could effectively fight back. Even if the U.S. government were to regulate prices, it would only affect a small portion of the company, since 64% of its sales originate outside the US.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 11:30 AM EDT Company Participants Alexander Hardy - President, CEO & Director Brian Mueller - Executive VP of Finance, CFO & Principal Accounting Officer Conference Call Participants Sean Laaman - Morgan Stanley, Research Division Presentation Sean Laaman Head of Healthcare Rese...

Children who received VOXZOGO showed anatomical improvements in spinal morphology VOXZOGO continued to significantly improve growth in children who received the medicine after puberty onset SAN RAFAEL, Calif. , Sept. 8, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced new data from 14 studies were presented at the American Society for Bone and Mineral Research 20...

New data from Phase 3 PEGASUS study demonstrates a 49.7% decrease in mean blood Phe levels in adolescents aged 12-17 treated with PALYNZIQ BioMarin's planned submission to global health authorities on track for second half of 2025 SAN RAFAEL, Calif. , Sept. 6, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced new data characterizing the efficacy and safety of PALY...

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN ) Wells Fargo 20th Annual Healthcare Conference 2025 September 4, 2025 8:45 AM EDT Company Participants Gregory Friberg - Executive VP and Chief Research & Development Officer Conference Call Participants Mohit Bansal - Wells Fargo Securities, LLC, Research Division Presentation Mohit Bansal Senior Equity Analyst All right. Thank you very much for joini...

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN ) Cantor Global Healthcare Conference 2025 September 3, 2025 8:00 AM EDT Company Participants Gregory Friberg - Executive VP and Chief Research & Development Officer Conference Call Participants Olivia Brayer - Cantor Fitzgerald & Co., Research Division Presentation Olivia Brayer Research Analyst Okay. Great. Hey, good morning, everyone.

Cantor Global Healthcare Conference, September 3 at 8:00 am EST Wells Fargo Healthcare Conference, September 4 at 8:45 am EST Morgan Stanley Global Healthcare Conference, September 9 at 11:30 am EST SAN RAFAEL, Calif. , Aug. 27, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will present at upcoming investor conferences in September.

BioMarin's revenue growth is strong, with Q2 2025 revenues up 16% year-over-year and full-year guidance raised to $3.125–$3.2 billion. The Inozyme acquisition brings late-stage BMN 401 for ENPP1 deficiency, with pivotal phase 3 data expected in 1H 2026 and potential first-mover advantage. Voxzogo and Palynziq continue to drive growth, with label expansions and new pipeline candidates like BMN 3...